Tumour vascular disrupting agents: Combating treatment resistance

British Journal of Radiology

Volumn 81, Issue SPECIAL ISSUE, 2008, Pages

  Tozer, Gillian M ^a   Kanthou, C ^a   Lewis, G ^b   Prise, V E ^b   Vojnovic, B ^b   Hill, S A ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANTINEOPLASTIC AGENT; AQ 4; AQ4; ARSENIC TRIOXIDE; AURISTATIN PE; BEVACIZUMAB; COLCHICINE; COMBRESTATIN A4; COMBRESTATIN A4 PHOSPHATE; COMBRETASTATIN; COMBRETASTATIN A1 PHOSPHATE; EXHERIN; FLUOROURACIL; GLUCOSE REGULATED PROTEIN 78; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; N ACETYLCOLCHINOL PHOSPHATE; NITRIC OXIDE SYNTHASE INHIBITOR; NPI 2358; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; TAXANE DERIVATIVE; TIRAPAZAMINE; UNCLASSIFIED DRUG; VANDETANIB; VASCULAR TARGETING AGENT; VINCA ALKALOID; ZYBRESTAT;

ANGIOGENESIS; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL JUNCTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMBRETUM; CONFERENCE PAPER; CYTOSKELETON; DRUG INDUCED HEADACHE; DYSPNEA; EXPERIMENTAL MOUSE; EXPERIMENTAL NEOPLASM; FATIGUE; GENE CONTROL; HEADACHE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPOXIA; MICROCIRCULATION; MONOTHERAPY; NAUSEA; NEUROBLASTOMA CELL; NEUROLOGIC DISEASE; NONHUMAN; RADIOSENSITIVITY; THYROID CANCER; TUMOR; TUMOR BLOOD FLOW; TUMOR CELL; UPREGULATION; VOMITING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOOD VESSELS; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; HUMANS; MICE; MICROTUBULES; NEOPLASMS; RATS; STILBENES; TUBULIN MODULATORS;

EID: 55449122145     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/36205483     Document Type: Conference Paper

References (72)

1. Baguley BC. Antivascular therapy of cancer: DMXAA. Lancet Oncol 2003;4:141-8.
2. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005;5:423-35.
3. Denekamp J, Hobson B. Endothelial cell proliferation in experimental tumours. Br J Cancer 1982;46:711-20.
4. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000;60:1388-93.
5. Denekamp J. Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer 1982;45:136-9.
6. Denekamp J, Hill SA, Hobson B. Vascular occlusion and tumour cell death. Eur J Cancer Clin Oncl 1983;19:271-5.
7. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
8. Burrows FJ, Thorpe PE. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci U S A 1993;90:8996-9000.
9. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005;5:436-46.
10. Boyland E, Boyland ME. Studies in tissue metabolism. IX. The action of colchicine and B. typhosus extract. Biochem J 1937;31:454-60.
11. Algire GH, Legallais FY, Anderson BF. Vascular reactions of normal and malignant tissues in vivo. VI. The role of hypotension in the action of components of podophyllotoxin on transplanted sarcomas. J Natl Cancer Inst 1954;14:879-87.
12. Baguley BC, Holdaway KM, Thomsen LL, Zhuang L, Zwi LJ. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer 1991;27:482-7.
13. Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ. Vinca alkaloids: anti-vascular effects in a murine tumour. Eur J Cancer 1993;9:1320-4.
14. Hill SA, Sampson LE, Chaplin DJ. Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid. Int J Cancer 1995;63:119-23.
15. Chaplin DJ, Pettit GR, Parkins CS, Hill SA. Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br J Cancer 1996;74:S86-8.
16. Pettit GR, Temple C, Narayanan VL, Varma R, Simpson MJ, Boyd MR, et al. Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des 1995;10:299-309.
17. Dark GD, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997;57:1829-34.
18. Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 2001;61:6413-22.
19. Pettit GR, Lippert III JW. Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs. Anticancer Drug Des 2000;15:203-16.
20. Hill SA, Tozer GM, Chaplin DJ. Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503. Anticancer Res 2002;22:1453-8.
21. Holwell SE, Cooper PA, Grosios K, Lippert JWr, Pettit GR, Shnyder SD, et al. Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo vascular effects in experimental tumours. Anticancer Res 2002;22:707-11.
22. Hori K, Saito S, Nihei Y, Suzuki M, Sato Y. Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700. Jpn J Cancer Res 1999;90:1026-38.
23. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002;62:3408-16.
24. Gadgeel SM, LoRusso PM, Wozniak AJ, Wheeler C. A dose-escalation study of the novel vascular-targeting agent, ZD6126, in patients with solid tumors (Abstract 438). Proc Am Soc Clin Oncol 21: 2002.
25. Galbraith SM, Rustin GJ, Lodge MA, Taylor NJ, Stirling JJ, Jameson M, et al. Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 2002;20:3826-40.
26. Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 2003;21:2823-30.
27. Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003;21:2831-42.
28. Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003;21:4428-38.
29. Tolcher AW, Forero L, Celio P, Hammond LA, Patnaik A, Hill M, et al. Phase I, pharmacokinetic, and DCE-MRI correlative study of AVE8062A, an antivascular combretastatin analogue, administered weekly for 3 weeks every 28-days. Proc Am Soc Clin Oncol 22: 2003. (Abstract 834.)
30. Evelhoch JL, LoRusso PM, He Z, DelProposto Z, Polin L, Corbett TH, et al. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 2004;10:3650-7.
31. Young SL, Chaplin DJ. Combretastatin A4 phosphate: background and current clinical status. Expert Opin Invest Drugs 2004;13:1171-82.
32. Prise VE, Honess DJ, Stratford MRL, Wilson J, Tozer GM. The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. Int J Oncol 2002;21:717-26.
33. Kanthou C, Tozer GM. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 2002;99:2060-9.
34. Vincent L, Kermani P, Young LM, Cheng J, Zhang F, Shido K, et al. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest 2005;115:2992-3006.
35. Kanthou C, Tozer GM. Tumour targeting by microtubule-depolymerizing vascular disrupting agents. Exp Opin Ther Targets 2007;11:1443-57.
36. Reyes-Aldasoro CC, Wilson I, Prise VE, Barber PR, Ameerbeg M, Vojnovic B, et al. Estimation of apparent tumour vascular permeability from multiphoton fluorescence microscopic images of P22 rat sarcomas in vivo. Microcirculation 2008;15:68-79.
37. Ley CD, Horsman MR, Kristjansen PE. Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressure. Neoplasia 2007;9:108-12.
38. Hori K, Saito S. Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis. Br J Cancer 2003;89:1334-44.
39. Lominadze D, Mchedlishvili G. Red blood cell behaviour at low flow rate in microvessels. Microvasc Res 1999;58:187-9.
40. Badn W, Kalliomaki S, Widegren B, Sjogren HO. Low-dose combretastatin A4 phosphate enhances the immune response of tumor hosts to experimental colon carcinoma. Clin Cancer Res 2006;12:4714-9.
41. Kanthou C, Greco O, Stratford A, Cook I, Knight R, Benzakour O, et al. The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death. Am J Pathol 2004;165:1401-11.
42. Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MRL, et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res. 1999;59:1626-34.
43. Sevick EM, Jain RK. Geometric resistance to blood flow in solid tumors ex vivo: effects of tumor size and perfusion pressure. Cancer Res 1989;49:3506-12.
44. Tozer GM, Lewis S, Michalowski A, Aber V. The relationship between regional variations in blood flow and histology in a transplanted rat fibrosarcoma. Br J Cancer 1990;61:250-7.
45. Wehbe H, Kearney CM, Pinney KG. Combretastatin A-4 resistance in H460 human lung carcinoma demonstrates distinctive alterations in beta-tubulin isotype expression. Anticancer Res 2005;25:3865-70.
46. Boucher Y, Baxter LT, Jain RK. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 1990;50:4478-84.
47. Milosevic MF, Fyles AW, Hill RP. The relationship between elevated interstitial fluid pressure and blood flow in tumors: a bioengineering analysis. Int J Radiat Oncol Biol Phys 1999;43:1111-23.
48. Beauregard DA, Hill SA, Chaplin DJ, Brindle KM. The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res 2001;61:6811-5.
49. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002;160:985-1000.
50. Jin N, Hatton N, Swartz DR, Xia X, Harrington MA, Larsen SH, et al. Hypoxia activates jun-N-terminal kinase, extracellular signal-regulated protein kinase, and p38 kinase in pulmonary arteries. Am J Respir Cell Mol Biol 2000;23:593-601.
51. Tozer GM, Cross NA, Barber PA, Björndahl MA, Greco O, Harris S, et al. Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumours. Cancer Res 2008;68:2301-11.
52. Honess DJ, Hylands, F, Chaplin, DJ, Tozer, GM. Comparison of strategies to overcome the hypertensive effect of combretastatin-A-4-phosphate in a rat model. Br J Cancer 2002;86:S118.
53. Murata R, Siemann DW, Overgaard J, Horsman HR. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother Oncol 2001;60:155-61.
54. Siemann DW, Rojiani AM. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2002;53:164-71.
55. Horsman MR, Siemann DW. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 2006;66:11520-39.
56. Grosios K, Loadman PM, Swaine DJ, Pettit GR, Bibby MC. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res 2000;20:229-34.
57. Li L, Rojiani A, Siemann D. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int J Radiat Oncol Biol Phys 1998;42:899-903.
58. Ng QS, Goh V, Carnell D, Meer K, Padhani AR, Saunders MI, et al. Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2007;67:1375-80.
59. Pedley RB, Boden JA, Boden R, Boxer GM, Flynn AA, Keep PA, et al. Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents. Cancer Res 1996;56:3293-300.
60. Pedley RB, Hill SA, Boxer GM, Flynn AA, Boden R, Watson R, et al. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate. Cancer Res 2001;61:4716-22.
61. Sengupta S, Eavarone D, Capila I, Zhao G, Watson N, Kiziltepe T, et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 2005;436:568-72.
62. Pattillo CB, Sari-Sarraf F, Nallamothu R, Moore BM, Wood GC, Kiani MF. Targeting of the antivascular drug combretastatin to irradiated tumors results in tumor growth delay. Pharm Res 2005;22:1117-20.
63. El-Emir E, Boxer GM, Petrie IA, Boden RW, Dearling JL, Begent RH, et al. Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice. Eur J Cancer 2005;41:799-806.
64. Boehle AS, Sipos B, Kliche U, Kalthoff H, Dohrmann P. Combretastatin A-4 prodrug inhibits growth of human non-small cell lung cancer in a murine xenotransplant model. Ann Thorac Surg 2001;71:1657-65.
65. Sheng Y, Hua J, Pinney KG, Garner CM, Kane RR, Prezioso JA, et al. Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis. Int J Cancer 2004;111:604-10.
66. Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006;313:1785-7.
67. Siemann DW, Shi W. Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. Int J Radiat Oncol Biol Phys 2004;60:1233-40.
68. Workman P, Stratford IJ. The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev. 1993;12:73-82.
69. Theys J, Landuyt W, Nuyts S, van Mellaert L, Van Oosterom A, Lambin P, et al. Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum. Cancer Gene Ther 2001;8:294-7.
70. Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ, Wilson WR. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4- acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer 1998;78:439-45.
71. Patterson LH, McKeown SR. AQ4N: a new approach to hypoxia-activated cancer chemotherapy. Br J Cancer 2000;83:1589-93.
72. Dong D, Ko B, Baumeister P, Swenson S, Costa F, Markland F, et al. Vascular targeting and antiangiogenesis agents induce drug resistance effector GRP78 within the tumor microenvironment. Cancer Res 2005;65:5785-91.